Shifts in cellular metabolism are central to activation, differentiation and proliferation of inflammatory cells and can contribute to the pathogenesis of inflammatory diseases. Integrating metabolomics data with other omics data is a major challenge but might enable clinicians to stratify stages of disease and response to therapy in patients with rheumatoid arthritis.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Ajeganova, S. & Huizinga, T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther. Adv. Musculoskelet. Dis. 9, 249–262 (2017).
Teitsma, X. M. et al. Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology. Arthritis Res. Ther. 20, 230 (2018).
DeBerardinis, R. J. & Thompson, C. B. Cellular metabolism and disease: what do metabolic outliers teach us? Cell 148, 1132–1144 (2012).
Bijlsma, J. W. J. et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388, 343–355 (2016).
Kanarek, N. et al. Histidine catabolism is a major determinant of methotrexate sensitivity. Nature 559, 632–636 (2018).
Teitsma, X. M. et al. Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy. Arthritis Res. Ther. 19, 10 (2017).
Teitsma, X. M. et al. Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2018-213767 (2018).
Wang, J. et al. IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis. BMJ Open 3, e003199 (2013).
Kapoor, S. R. et al. Metabolic profiling predicts response to anti-TNFα therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 65, 1448–1456 (2013).
Young, S. P. et al. The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheumatol. 65, 2015–2023 (2013).
C. M. M. is funded by a Research Fellowship from the National Institute for Health Research.
C. M. M. declares that she has received honoraria from Pfizer. S.P.Y. declares no competing interests.
About this article
Cite this article
McGrath, C.M., Young, S.P. Can metabolomic profiling predict response to therapy?. Nat Rev Rheumatol 15, 129–130 (2019). https://doi.org/10.1038/s41584-018-0136-z
BMC Medical Genomics (2020)